Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Martijnse IS, Dudink RL, Kusters M, Vermeer TA, West NP, Nieuwenhuijzen GA, van Lijnschoten I, Martijn H, Creemers GJ, Lemmens VE, van de Velde CJ, Sebag-Montefiore D, Glynne-Jones R, Quirke P, Rutten HJ. Martijnse IS, et al. Among authors: creemers gj. Ann Surg Oncol. 2012 Feb;19(2):392-401. doi: 10.1245/s10434-011-1955-1. Epub 2011 Jul 27. Ann Surg Oncol. 2012. PMID: 21792506 Clinical Trial.
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.
Hospers GA, Schaapveld M, Nortier JW, Wils J, van Bochove A, de Jong RS, Creemers GJ, Erjavec Z, de Gooyer DJ, Slee PH, Gerrits CJ, Smit JM, Mulder NH. Hospers GA, et al. Among authors: creemers gj. Ann Oncol. 2006 Mar;17(3):443-9. doi: 10.1093/annonc/mdj104. Ann Oncol. 2006. PMID: 16500914 Free article. Clinical Trial.
A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
van de Schoot L, Romme EA, van der Sangen MJ, Creemers GJ, van Lijnschoten G, van Driel OJ, Rutten HJ, Nieuwenhuijzen GA. van de Schoot L, et al. Among authors: creemers gj. Ann Surg Oncol. 2008 Jan;15(1):88-95. doi: 10.1245/s10434-007-9582-6. Epub 2007 Sep 26. Ann Surg Oncol. 2008. PMID: 17896144 Free PMC article. Clinical Trial.
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF, Punt CJ. Tol J, et al. Among authors: creemers gj. Ann Oncol. 2008 Apr;19(4):734-8. doi: 10.1093/annonc/mdm607. Epub 2008 Feb 13. Ann Oncol. 2008. PMID: 18272912 Free article. Clinical Trial.
Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer.
Dresen RC, Gosens MJ, Martijn H, Nieuwenhuijzen GA, Creemers GJ, Daniels-Gooszen AW, van den Brule AJ, van den Berg HA, Rutten HJ. Dresen RC, et al. Among authors: creemers gj. Ann Surg Oncol. 2008 Jul;15(7):1937-47. doi: 10.1245/s10434-008-9896-z. Epub 2008 Apr 4. Ann Surg Oncol. 2008. PMID: 18389321 Free PMC article.
Patterns of local recurrence in locally advanced rectal cancer after intra-operative radiotherapy containing multimodality treatment.
Kusters M, Holman FA, Martijn H, Nieuwenhuijzen GA, Creemers GJ, Daniels-Gooszen AW, van den Berg HA, van den Brule AJ, van de Velde CJ, Rutten HJ. Kusters M, et al. Among authors: creemers gj. Radiother Oncol. 2009 Aug;92(2):221-5. doi: 10.1016/j.radonc.2009.03.002. Epub 2009 Mar 30. Radiother Oncol. 2009. PMID: 19339070
222 results